Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 fusion |
| Therapy | Lirafugratinib |
| Indication/Tumor Type | cholangiocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 fusion | cholangiocarcinoma | predicted - sensitive | Lirafugratinib | FDA approved | Actionable | In a Phase I/II trial (ReFocus) that supported FDA approval, Lyrfigtu (lirafugratinib) treatment was safe and resulted in an objetive response rate of 47% (53/114, 3 complete and 50 partial responses), a median duration of response of 11.8 mo, a meidan progression-free survival of 11.3 mo, and median overall survial of 22.8 mo in FGFR inhibitor-naive cholangiocarcinoma patients harboring FGFR2 fusions or rearrangements (J Clin Oncol 44, 2026 (suppl 2; abstr 476); NCT04526106). | detail... detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2 f/r). | Full reference... | |
| Lyrfigtu (lirafugratinib) FDA Drug Label | Full reference... |